Comparative Pharmacology
Head-to-head clinical analysis: KAINAIR versus THEOPHYL 225.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KAINAIR versus THEOPHYL 225.
KAINAIR vs THEOPHYL-225
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Kainair is a selective agonist for kainate receptors, which are ionotropic glutamate receptors. It depolarizes neurons by increasing sodium and calcium conductance, leading to excitatory neurotransmission and neurotoxicity at high doses.
Theophylline is a methylxanthine that inhibits phosphodiesterase, leading to increased intracellular cAMP levels, and antagonizes adenosine receptors (A1, A2). This results in bronchodilation, reduced airway inflammation, and enhanced diaphragmatic contractility.
25 mg subcutaneously three times daily.
225 mg orally every 6 hours; adjust based on serum theophylline levels to maintain therapeutic range 10-20 mcg/mL.
None Documented
None Documented
3-5 hours, prolonging in renal impairment (up to 12-18 hours in GFR <30 mL/min).
Terminal half-life: 3–12 hours (adults); shorter (1–5 hours) in children and smokers; prolonged in hepatic cirrhosis, heart failure, or elderly. Steady-state achieved in 1–2 days.
Primarily renal (approximately 90% unchanged drug within 24 hours), with minor biliary/fecal elimination (<10%).
Renal: 10% unchanged; hepatic metabolism (CYP1A2, CYP3A4) accounts for ~90% of elimination, with metabolites (e.g., 3-methylxanthine, 1,3-dimethyluric acid) excreted renally.
Category C
Category C
Bronchodilator
Bronchodilator